Overview

• Global Phase 3 BaxHTN enrolled 796 patients across 214 sites, most with resistant hypertension and already on multiple medications.
• At 12 weeks, baxdrostat 1 mg and 2 mg reduced seated systolic pressure by placebo‑adjusted 8.7 and 9.8 mmHg, with 39–40% achieving 6 mmol/L, and no adrenocortical insufficiency; AstraZeneca reports plans to seek approval by the end of 2025.